Study design: Experimental study. Objectives: To investigate the effects of endothelin-receptor antagonist Bosentan on the spinal neural apoptosis in rats with ischemic reperfusion (IR) injury. Setting: Department of Neurosurgery, the Second Affiliated Hospital, Xi'an Jiaotong University School of Medcine, Xi'an, Shaanxi Province, China Methods: Sprague-Dawley Rats were randomly divided into two groups, saline (IRS, n ¼ 48) and Bosentan (IRB, n ¼ 48) treatment, respectively, when reperfused in 6 h, 12 h, 24 h, 3 days, 5 days and 7 days. Immunohistochemical staining was used to assess endothelin-1 (ET-1), endothelin receptor type A (ETR A ), endothelin receptor type B (ETR B ), Bcl-2, Bax, Caspase-8, Caspase-9 and Caspase-3 expression. ET-1 and its receptor in spinal cord tissue were evaluated by real-time PCR. Plasma ET-1 concentration was also detected using radioimmunoassay. Results: Compared with the group IRS, plasma concentration of ET-1 in group IRB was significantly increased at each time point (Po0.05) and peaked at 24 h (Po0.01). ETR B expression in group IRB was significantly higher than group IRS at each time point (Po0.05) and peaked at day 3 (Po0.01). The difference in the expression of ETR A was not statistically significant in the group IRS and IRB (P40.05). The apoptosis rate in group IRB was significantly decreased at each time point (Po0.05). The protein expressions of Bcl-2, Bax, Caspase-8, Caspase-9 and Caspase-3 were significantly increased in response to Bosentan treatment after IR. Conclusion: These results suggest Bosentan decreases apoptosis rate after IR injury in the spinal cord, possibly through the ET-1-ETR B signaling pathway.
INTRODUCTION
Globally, the incidence rate, death rate and age of spinal cord injury may vary, but its complications, high cost and poor prognosis 1 are common throughout the world. Spinal cord ischemic reperfusion injury (SIRI) is an essential step in secondary injury during the recovery of spinal cord blood flow following thoraco-abdominal aortic surgery. 2 SIRI can cause various complications such as paraplegia, decubitus and pulmonary infection. 3 Present studies suggest that the pathophysiological mechanisms underlying SIRI are complicated, including inflammatory factor release, endothelial cell dysfunction and neuronal apoptosis. 4 Several studies have showed that the mechanism involved in apoptosis includes the upregulation of Akt protein and caspase-3, 5 as well as endoplasmic reticulum stress 6 in IR neural cells. A series of drugs have been administered in clinics and experiments have been conducted to prevent or treat SIRI. 7 Endothelin has been shown to have an essentially damaging effect on myocardia 8 and hepatic 9 reperfusion injury. Endothelin plays a role through the action of endothelin receptors, which are G protein-coupled receptors, including ETR A and ETR B . There is abundant ETR A expression in vascular smooth muscle cells where its activation leads to a long-lasting contraction by eliciting an increase of intracellular calcium. ETR B is mainly expressed in endothelial cells where it leads to relaxation of vascular smooth muscle cells by inducing the release of nitric oxide, 10,11 thereby. Bosentan, which is a nonselective endothelin-receptor antagonist, 12 has been shown to greatly ameliorate the myocardium 13 and skeletal muscle 14 injury after IR. However, there is no study on its protective role in SIRI to date. In this study, a rat model of SIRI was established and Bosentan was applied. It was found that Bosentan could reduce neuronal apoptosis following SIRI. Interestingly, endothelin-1 (ET-1) and ETR B were significantly upregulated. It has raised the possibility that Bosentan could affect the apoptosis progress via ET-1-ETR B signaling pathway. Therefore, it will enhance the understanding of the pathology of SIRI and provide theoretical evidence for future medical management.
MATERIALS AND METHODS

Experimental animals and grouping
A total of 96 male Spraque-Dawley rats weighing between 250 and 300 g were purchased from the Animal Center of Xi'an Jiaotong University, China. Animals were randomly divided into IR þ saline (IRS, n ¼ 48) and the IR þ Bosentan (IRB, n ¼ 48). Group IRS and IRB were divided into another six groups, according to reperfusion times: 6 h, 12 h, 24h, 3 days, 5 days and 7 days. Group IRB was injected with Bosentan (Actelion Pharmaceuticals Ltd., Allschwil, Switzerland, 5 mg kg À1 body weight) via the caudal vein at 20 min prior to reperfusion, followed by caudal vein injection with an equal dose of Bosentan at 24 h intervals until killed. Group IRS was injected with an equal dose of saline via the caudal vein at each time point. 13 Establishment of rat models of SIRI, serum and spinal cord specimen collection
After fasting 12 h before surgery, the rats were intraperitoneally anesthetized with 0.75% amobarbital sodium (4 ml kg À1 ). Ischemia of the lumbar spinal cord was induced by clamping the abdominal aorta with a mini aneurysm clamp for 60 min, followed by 6 h, 12 h, 24 h, 3 days, 5 days and 7 days of reperfusion. 15 The occlusion sites were approximately 0.5 cm below the left and just proximal to the aortic bifurcation. Sham operation rats underwent the same operative procedure with the exception of aortic occlusion. Blood samples (2 ml) were collected from the inferior vena cava and stored in an additional tube containing 7.5% disodium ethylenediamine tetra-acetic acid (30 ml) and aprotinin (40 ml; blood volume could be increased or decreased according to proportion), then centrifuged at 3000 r.p.m. for 10 min at 4 1C. Plasma was separated and stored at À70 1C. After reperfusion, the rats in each group were anesthetized. A median incision was made on the back, and the vertebral plate was opened to expose L 2 -L 5 spinal cord. L 3 spinal cord was dissociated and obtained for future analysis.
Plasma ET-1 content was determined using radioimmunoassay. In accordance with instructions for the 125 I endothelin radioimmunoassay kit (General Hospital of Chinese PLA, Beijing, China), plasma was measured and standard curves were drawn. ET-1 concentrations were calculated. 16 Immunohistochemical staining for ET-1, ETR A , ETR B, Bcl-2, Bax, Caspase-8, Caspase-9 and Caspase-3 expression
Transverse sections 4 mm thick were cut and mounted on glass slides treated with silica after paraffin embedding. The slides were deparaffinized with graded concentrations of xylene and ethanol. Tissue sections were treated with block serum for 30 min at room temperature to block non-specific binding sites. Thereafter, the sections were incubated with antibodies against ET-1 (1:200 dilution, rabbit polyclonal, Abcam, Cambridge, MA, USA), ETR A (1:50 dilution, rabbit polyclonal, Millipore, Billerica, MA, USA), ETR B (1:50 dilution, rabbit polyclonal, Millipore), and Bcl-2, Bax, Caspase-8, Caspase-9, Caspase-3 (1:50 dilution, rabbit polyclonal, Thermo Scientific, Germaring, Germany) at 4 1C overnight. Specimens were incubated with secondary antibody and horseradish peroxidase complex solution in accordance with instructions given in the immunohistochemical staining kit (Beijing Biosynthesis Biotechnology Co., Ltd., Beijing, China). Samples were then developed with 3, 3 0 -diaminobenzidine (Beijing Biosynthesis Biotechnology Co., Ltd.), and mounted onto slides. Sections were then imaged, analyzed and observed by another investigator, who was not familiar with the study design. Five sections of each rat from each group were made. Five different vision fields of a section were analyzed by an image analysis collection system (Q553Cw; Leica, Wetzlar, Germany) and the average optical densities (grey value) were measured. Gray value is inversely proportional to the protein expression in our analysis system.
Quantitative real-time PCR for ET-1 and its receptor in spinal cord tissue
The mRNA was extracted and reverse transcribed to cDNA with a Geneamp PCR System 9700 (Applied Biosystems, Foster, CA, USA) in accordance with RevertAid First Strand cDNA Synthesis Kit #K1622 (Fermentas, Vilnius, Lithuania). DNA was amplified with corresponding primers using 2 ml of reverse transcription solution as a template. PCR was conducted on an ABI Prism 7000 Sequence Detection System (Applied Biosystems, Foster, CA, USA). With a SYBR Green Real-time PCR Master Mix kit (TOYOBO, Osaka, Japan), total reaction volume was 25 ml. Parallel wells were used for all specimens and b-actin was utilized as internal reference. 16 Terminal deoxyribonucleotidyl transferse (TdT)-mediated biotin-16-dUTP nick-end labeling (TUNEL) assay Paraffin sections were prepared as for hematoxylin-eosin staining. Sections were dewaxed and hydrated. In accordance with instructions given for the TUNEL kit (Promega, Madison, WI, USA), cells were quantified under a 40 Â microscope (Q553Cw; Leica). Five visual fields of tissue were randomly selected. The number of TUNEL-positive cells was separately quantified for every 50 cells in the field. Apoptotic index was calculated by the following formula: the number of apoptotic cells/total number of cells Â 100%. 17 
Statistical analysis
The data was analyzed using SPSS 17.0 for Windows (Chicago, IL, USA). The results were expressed as the mean±standard error. Comparisons between groups were performed with Kruskal-Wallis analysis of variance and One-Way Anova. For all analyses, statistical significance was defined at Po0.05.
We certify that all applicable institutional and governmental regulations concerning the ethical use of animals were followed during the course of this research.
RESULTS
The treatment of Bosentan after IR increased the expression of ET-1 Compared with the group IRS, protein expression of plasma ET-1 in group IRB significantly increased at each time point (Po0.05) and peaked at 24 h (Figure 1c ). Gray value is inversely proportional to the protein expression in our analysis system. Protein and mRNA expression of ET-1 were also significantly increased and peaked at same time point in group IRB (Figures 1a, b and d) .
Bosentan increased ETR B expression following IR
Gray value is inversely proportional to the protein expression in our analysis system. Protein expression of ETR B in group IRB was significantly higher than group IRS at each time point (Po0.05) (Figures 2a and b ) and peaked at day 3 ( Figure 2b) . Compared with the group IRS, mRNA expression of ETR B was also significantly increased (Po0.05) and peaked at 24 h (Figure 2c ).
Bosentan had no effect on ETR A expression following IR ETR A was only expressed in astrocytes (Figure 3a) , and there was no statistically significant difference in the protein and mRNA expression of ETR A in the group IRS and IRB (P40.05) (Figures 3b and c) .
The treatment of Bosentan decreased cell apoptosis induced by IR
Compared with the group IRS, the proportion of apoptotic cells in group IRB significantly decreased at each time point (Po0.05) (Figure 4a ). Gray value is inversely proportional to the protein expression in our analysis system. The protein expressions of Bcl-2, Bax, Caspase-8, Caspase-9 and Caspase-3 were significantly decreased in response to Bosentan treatment after IR (Figures 4b-e) .
DISCUSSION
In this study, we found that the administration of Bosentan after IR significantly increased expression of ET-1 and ETR B . The proportion of apoptotic cells and gene in group IRB significantly decreased following the treatment with Bosentan.
Endothelin has three isoforms (identified as ET-1, -2, -3) and binds to the ETR A and ETR B . 18 Endothelin and its receptors have essential pathophysiological effects during myocardial IR injury, 8 but few studies have investigated their effects on the central nervous system, especially during SIRI. Endothelin induces contraction by acting on ETR A and causes vasodilatation and endothelin scavenging by acting on ETR B in vascular endothelial cells. 19, 20 Bosentan, a nonselective ETR A and ETR B antagonist, blocks the biological effects of ET-1 and is approved by the Food and Drug Administration for use as an oral medication for the treatment of pulmonary hypertension. 21 Results from the present study suggested that plasma and tissue endothelin increased following Bosentan intervention, along with an increase in endothelin mRNA. The possible mechanism is that ETR B blockage reduced ET-1 internalization. A previous study confirmed that ET-1 exerts its biological effect by autocrine and paracrine action, resulting in induction of self-expression. 22 Differences in animal models, species and tissue specificity may also play a role in these various findings.
Our experiment confirmed that ETR B expression significantly increased in neuronal cytoplasm, nuclei and glial cells following IR and after Bosentan intervention, which varies from precious studies. 23 Prior studies demonstrated that under normal conditions, using immunofluorescence, ETR A expression was mainly visible in vascular endothelial cells and primary afferent nerve fibers, but ETR B expression was mainly detectable in radial glial cells as well as astrocytes, ependymal cells, vascular endothelial cells and smooth muscle cells in the gray matter and white matter. Stenman et al. 16 indicated that ETR B expression obviously increased in a rat model of cerebral ischemia/reperfusion at a transcriptional level, which was associated with inflammatory factors acting on DNA regulatory element. The current study verified that ETR B expression increased following Bosentan intervention at a transcriptional level. Whether increased endothelin expression upregulated ETR B expression via an unknown pathway requires further investigations.
Cell apoptosis is promoted when the BAX/BAX ratio is greater than the Bcl-2/BAX ratio. When Bcl-2 expression increased, cell death is suppressed. 24 BAX and Bcl-2 form a complex, which cannot alter the permeability of the mitochondrial membrane or induce cell apoptosis. Cytochrome C bound to apoptotic protease activating factor-1, results in apoptotic protease activating factor-1 oligomerization, which is a prerequisite for procaspase-9 activation. 25 Subsequently, caspase-3, caspase-7 and caspase-6 were activated. 25 In this study, Bcl-2 expression increased following Bosentan intervention, whereas Caspase-8 expression, involved in the death receptor pathway, decreased. These results indicated that Bosentan could protect the spinal cord by affecting the expression of apoptotic proteins. To verify this effect, TUNEL staining was utilized to detect apoptotic cells in tissue sections by measuring nuclear DNA fragments, with a high sensitivity and specificity. 26 In the current study, the proportion of apoptotic neurons in the spinal cord was remarkably decreased following treatment with Bosentan. The molecular mechanisms of the apoptosis-protecting effect achieved by Bosentan in spinal cord ischemia reperfusion need be evaluated in further studies. Our other study showed that Bosentan upregulated VEGF expression in blood and tissue, which can promote angiogenesis and may be the reason of the apoptosis-protecting effect in spinal cord ischemia reperfusion (unpublished data).
CONCLUSIONS
This study showed that Bosentan decreased apoptosis rate after IR injury of the spinal cord in a rat SIRI model, possibly through the ET-1-ETR B signaling pathway.
DATA ARCHIVING
There were no data to deposit.
